Skip to main content
. Author manuscript; available in PMC: 2010 Jun 25.
Published in final edited form as: Pharm Res. 2003 Sep;20(9):1485–1495. doi: 10.1023/a:1025774630993

Fig. 3.

Fig. 3

A, Specific caspase-3 activity in A549 cells. Control, untreated cells; NIM, nimesulide (40 μg/ml); DXR, doxorubicin (0.25 μg/ml); NIM+DXR, nimesulide (40 μg/ml) + doxorubicin (0.25 μg/ml). Data represent the mean ± SD of three experiments. Statistical significance of the difference in the caspase-3 activity: •NIM+DXR vs. control; NIM+DXR vs. NIM, p < 0.001; ★-NIM+DXR vs. DXR, p < 0.01. B, Electrophoresis of DNA from A549 cells. Lane M, 100 bp DNA marker; lane 1, untreated control cells; lane 2, nimesulide (80 μg/ml); lane 3, doxorubicin (0.25 μg/ml); lane 4, nimesulide (80 μg/ml) + doxorubicin (0.25 μg/ml).